Lentiviral particles allow easy gene delivery
Supplied ready to use
The Abingdon, UK-based firm supplies the new particles ready to use, eliminating the need for any lipids or transfection reagents. The company says these pre-made lentiviral particles are proven to deliver genes in a highly reproducible and controllable manner for the expression of more than 250 human proteins, mouse proteins, enzymes and fluorescent markers.
Using proprietary protocols based on co-expressed red fluorescent protein by a 2A peptide processing (SureTitre) or RSV promoter (Inducible system), these lentiviral particles enable real time monitoring of protein expression.
All AMSBIO lentiviral products are said to be easy and safe to use by simply adding the high titre particles (1 x 107 IFU/ml or higher) to cultured cells, and you will be able to confirm the specific target's expression under a fluorescent microscope after 48–72 hours.
AMSBIO lentiviral particles are packaged in culture medium with 10% FBS, in serum-free medium or concentrated in PBS for in vivo use.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part V)
Read moreAs therapies grow more complex, manufacturers must build commercial-scale thinking into early development, focus on meaningful monitoring and favour simplicity to keep production predictable
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part V)
As therapies grow more complex, manufacturers must build commercial-scale thinking into early development, focus on meaningful monitoring and favour simplicity to keep production predictable
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part IV)
Real-time monitoring, digital-first platforms and early scalability planning can help manufacturers to maintain quality, flexibility and speed as dosage forms become more sophisticated
Analysis
Inspection readiness should be part of normal operations
For routine surveillance inspections, readiness cannot depend on receiving advance notice. Inspection readiness should be embedded in everyday operations, while recognising that preparation may need to become more intensive ahead of a known regulatory milestone